Head and Neck Oncologic Surgery Fellowship Program

A Legacy of Leadership and Innovation



Memorial Sloan Kettering Cancer Center

Training the Future Leaders of Cancer Care

CONTENTS

HISTORY

For more than a century, the Head and Neck Service at Memorial Sloan Kettering Cancer Center has provided leadership and innovation in the field of head and neck surgery and oncology.

Memorial Sloan Kettering Cancer Center was founded in 1884 as New York Cancer Hospital on Manhattan's Upper West Side by a group that included John J. Astor and his wife, Charlotte.

The Head and Neck Service at Memorial Sloan-Kettering Cancer Center was established in 1914 and was the first service dedicated to the care of patients with head and neck cancers. Dr. Henry Janeway was appointed the first Chief of the Head and Neck Service and was a pioneer in the use of radiation therapy for patients with head and neck tumors. After his retirement in 1921, his successor Dr. Douglas Quick, continued Dr. Janeway's work with radium x-rays and radon seeds.

In 1934, Dr. Hayes Martin, the "father" of head and neck surgery as we know it today, was appointed Chief. Dr. Martin popularized fine-needle aspiration biopsy as a diagnostic pre-treatment procedure and also developed new surgical procedures for treating head and neck tumors, including the "Commando Operation," a radical treatment for oral cancer that involves removal of part of the mandible as well as a neck dissection. In addition to his clinical accomplishments, Dr. Martin was a devoted teacher and mentor to residents and fellows. In 1954, Dr. Martin founded the Society of Head and Neck Surgeons, one of the parent organizations of the American Head and Neck Society.

After Dr. Martin's retirement in 1957, Dr. Edgar Frazell was appointed the service's chief. Dr. Frazell was an international leader in the diagnosis and treatment of thyroid cancers. He also served as the president of the Society of Head and Neck surgeons in 1966.

Dr. Elliot Strong joined the Head and Neck Service in 1963 and became its Chief in 1969. During his time in this position, Dr. Strong contributed to major advances in the field, including new treatments stemming from surgeons collaborating with radiation and medical oncologists. Dr. Strong also promoted immediate reconstruction of surgical defects following resection of the primary tumor using local and free flaps. The one-year clinical fellowship he established in 1979 is the model still in use today.

Dr. Jatin Shah was recruited to MSK in 1974. During his first years on the service, Dr. Shah introduced myocutaneous flaps and free jejunal flaps, which opened the door to additional microvascular reconstruction techniques, including the fibular free flap described by Dr. David Hidalgo. Dr. Shah became Chief in 1992. By carefully selecting surgeons and recruiting them to the service,

Jatin Shah

Dr. Shah created a team that would lead the field of head and neck cancer in both clinical and translational research. During his 23 years as Chief, Dr. Shah became a world leader in the field of head and neck cancer and the service continued to be a center of excellence in patient care, research, and education. In 2015, Dr. Shah stepped down as Chief to dedicate more time towards the education of the next generation of head and neck surgeons, both within MSK and internationally through the Online Head and Neck Fellowship Program of the International Federation of Head and Neck Oncologic Societies, both of which he founded.

In 2015, Dr. Richard Wong, an MSK trained surgeon, and scientist was appointed chief of the Head and Neck Service to continue the legacy of leadership and innovation for the benefit of head and neck cancer patients.

Surgery

The Head and Neck Service cares for more than 3,172 new patients, performs approximately 1768 surgical procedures, and manages more than over 14,339 outpatient visits each year. As one of the largest referral centers in the world, MSK receives patients from the greater New York area, the United States, and around the globe.

With new cutting-edge diagnostic and therapeutic technologies, the Head and Neck service at MSK is always at the front. These include transoral robotic surgery (TORS), endoscopic skull base surgery and transoral laser microsurgery (TLM) for early laryngeal cancer.

Disease Management Team (DMT)

Our integrated disease management team (DMT) consists of head and neck surgeons, plastic and reconstructive surgeons, neurosurgeons, medical oncologists, radiation oncologists, pathologists, radiologists, basic scientists, speech and voice therapists and dedicated nursing staff.

The Head and Neck DMT is leading wide variety novel translational studies and clinical trials defining the role of genomics, precision oncology, immunotherapy, molecular serum and salivary markers, resistance mechanisms, the tumor microenvironment, de-escalation of therapy for human papilloma virus associated cancers, proton beam radiation, and other factors in the management of head and neck cancers.

FELLOWSHIP PROGRAM

Overview

The Head and Neck Oncologic Surgery Fellowship Program at Memorial Sloan Kettering Cancer Center is one of the most comprehensive and competitive programs in the United States. The fellowship program is accredited by the Advanced Training Council of the American Head and Neck Society (AHNS) and is designed for graduates of residency programs in otolaryngology, general surgery, and plastic surgery who seek state–of–the–art training in head and neck oncologic surgery and a multidisciplinary approach in management of head and neck cancer patients. The fellows are selected through the AHNS computerized matching system every year. The candidates are ranked according to their career goals, past achievements, and an in-person interview. The program offers a one-year clinical fellowship, a two-year combined clinical and research fellowship, or a three-year program that includes a clinical year and two years of basic research supported by a T32 training grant from the National Institutes of Health.

Clinical Training

The fellowship program provides intensive hands-on surgical training in complex ablative head and neck oncologic surgery and minimally invasive techniques. This includes composite resection of tumors of the oral cavity and oropharynx, craniofacial resection of sinonasal tumors, excision of advanced skin cancers, salivary gland tumors, early and advanced laryngeal and hypopharyngeal cancers, parapharyngeal space tumors, advanced thyroid cancers, trans-oral robotic-assisted surgery, trans-oral laser microsurgery, and endoscopic skull base surgery including the trans-nasal approach to pituitary and other skull base tumors. Local flaps and reconstruction are performed by the Head and Neck Service physicians while microvascular reconstruction is performed by members of the Plastic Surgery Service.

The clinical rotation consists of a 12-month period wherein fellows are responsible for preoperative and postoperative patient care and are involved in surgical operations under the direction of the attending surgeons. Each fellow performs 300 to 350 procedures during this clinical year.

Each year, Memorial Sloan Kettering diagnoses and treats more than 3,500 people with head and neck cancer. Our team includes more than 45 medical professionals who focus exclusively on these diseases.

Education

Didactic lectures and clinical case-based learning are emphasized during the fellowship. One key educational component is the tumor board. This is a multidisciplinary group in which complex medical decision-making takes place among the faculty through discussion of the literature and the expected risks, benefits, and alternatives of treatment.

Additional weekly lectures are given by the faculty on all subjects within head and neck surgical oncology. Fellows also gain experience by participating in outpatient clinics, rounds, lectures, seminars, journal club, and research conferences. Fellows have access to all conferences at Memorial Sloan Kettering Cancer Center.

There are currently approximately 50 formal conferences per year and 4-6 cancer-related lectures each week. Fellows may also enroll in various career enhancement programs at Weill Cornell Medical College and are invited to participate in external training activities that are organized by the Head and Neck Service, including a trans-oral endoscopic laser microsurgery course and the Current Concepts in Head and Neck Surgery course, both held annually. Fellows are also given an opportunity to supervise and instruct residents.

Research Opportunities

The research rotation consists of either one or two years, depending upon individual interests, performing clinical or basic research with an opportunity to focus on an aspect of head and neck oncology, including but not limited to genetics, molecular biology, chemo-prevention, experimental therapeutics, and health outcomes and health services research. An NIH-funded T32 research grant is available each year for those who are interested in accomplishing two years of full-time basic research.

Laboratory support is provided by a multidisciplinary team of collaborative scientists who mentor fellows in developing a hypothesis, determining focus, developing methodology, interpreting results, and publishing their laboratory work. Special emphasis is placed on developing skills for grant applications. Head and neck fellows have been very successful recipients of research awards during and after training. Fellows are encouraged to apply to granting agencies and national societies for support.

Richard J. Wong, MD, FACS

Attending Surgeon
Chief, Head and Neck Service
Memorial Sloan Kettering Cancer Center

Professor of Otolaryngology
Weill Cornell Medical College

Education: MD, Harvard Medical School

Residency: Harvard Otolaryngology Residency Program

Fellowship: Memorial Sloan Kettering Cancer Center

Richard Wong is the Chief of the Head and Neck Service. He leads a team of eleven head and neck surgeons who have expertise and national reputations in all aspects of head and neck oncologic surgery, including robotic surgery, transoral laser microsurgery, and endoscopic skull base surgery. Dr. Wong is a co-director of the Head and Neck Disease Management Team, and promotes multi-disciplinary approaches to patient management with team members from Medical Oncology, Radiation Oncology, Endocrinology, Plastic Surgery, Dentistry, and Speech and Swallowing.

Dr. Wong is committed towards fellow and resident education and is the Principal Investigator on a Head and Neck Surgical Oncology T32 Training Grant from the National Institutes of Health. He has also trained numerous research fellows, many of whom have gone on to develop their own independent research programs. He serves as the site director for the Cornell/Columbia otolaryngology residency program and is actively involved in the training and evaluation of residents and clinical fellows.

Dr. Wong has particular expertise in the surgical removal of thyroid cancer, nodal metastases from thyroid cancer, and recurrent thyroid cancer. He also has a strong interest in treating all aspects of head and neck oncology, including oral cancer, salivary tumors, malignant melanoma, and a variety of other tumor types.

Dr. Wong is a scientist and the Principal Investigator of an R01 grant from the National Cancer Institute. His laboratory group explores the molecular and cellular mechanisms underlying cancer perineural invasion. Dr. Wong directs an NIH-funded research laboratory that seeks to elucidate the cellular and molecular mechanisms of perineural invasion. His group collaborates with investigators from the Sloan Kettering Institute in cell biology and infectious disease. Dr. Wong's research previously focused on investigating how replication-competent, genetically modified oncolytic viruses may be used for the therapy of solid tumors.

Dr. Wong's laboratory has been previously been funded by grants from the National Institute of Dental and Craniofacial Research, the American Society of Clinical Oncology, the American College of Surgeons, the American Head and Neck Society, and the Flight Attendant Medical Research Institute.

Selected Publications

Deborde S, Omelchenko T, Lyubchik A, Zhou Y, He S, McNamara WF, Chernichenko N, Lee SY, Barajas F, Chen CH, Bakst RL, Vakiani E, He S, Hall A, Wong RJ. Schwann cells induce cancer cell disperion and invasion. *J Clin Invest*. 2016; 126:1538-54.

He S, Chen CH, Chernichenko N, et al. GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. *Proc Natl Acad Sci*. 2014;111(19):E2008-17.

Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. *J Natl Cancer Instit*. 2010;102:107-18.

He S, He S, Chen CH, Deborde S, Bakst RL, Chernichenko N, McNamara WF, Lee SY, Barajas F, Yu Z, Al-Ahmadie HA, Wong RJ. The chemokine (CCL-CCR2) signaling axis mediates perineural invasion. *Mol Cancer Res*. 2015;13:380-90.

Bakst RL, Lee N, He S, et al. Radiation impairs perineural invasion by modulating the nerve microenvironment. *PLoS One*. 2012;7:e39925.

Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. *PLoS One*. 2013;8:e7768.

Chen CH, Chen W Y, Lin SF, Wong RJ. Epithelial mesenchymal transition enhances response to oncolytic herpes viral therapy through nectin-1. *Hum GeneTher*. 2014 [Epub ahead of print].

Yu Z, Li S, Brader P, et al. Oncolytic vaccinia viral therapy of squamous cell carcinoma. *Mol Cancer*. 2009;8:45.

Lin SF, Price DL, Chen CH, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. *J Clin Endocrinol Metab*. 2008;93:4403-7.

Lin SF, Gao SP, Price DL, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. *Clin Cancer Res*. 2008;14:1519-28.

Yu Z, Adusumilli P, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. *Mol Ther*. 2007;15:103-13.

Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18) F]f luorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol*. 2002;20:4199-208.

Jay O. Boyle, MD, FACS

Associate Attending Surgeon
Director, Fellowship Training Program in Head and Neck Surgery
Memorial Sloan Kettering Cancer Center

Associate Professor of Otolaryngology
Weill Cornell Medical College

Education: MD, University of Arizona College of Medicine

Residency: The Johns Hopkins Hospital

Fellowship: Memorial Sloan Kettering Cancer
University of Arizona Cancer Center



Dr. Boyle joined MSK in 1999 and was named Director of the fellowship training program in 2002. Dr. Boyle has collaborated with Dr. Andrew Dannenberg to study carcinogenesis and prevention of tobacco smoke–related cancers. Together with more than a dozen head and neck fellows who trained with them over a 15-year period, they translated many important findings into clinical trials for cancer prevention. Dr. Boyle received NIH grants to study the efficacy of Cox-2 inhibitors and NSAIDS in oral leukoplakia. He has collaborated with investigators around the country and the world to study the prevention of cancer with EGFR inhibitors and PPAR gamma ligands.

Dr. Boyle has served on the executive council of the American Head and Neck Society as Research Committee Chair and Program Chair and on the executive council of the International Academy of Oral Oncology. He is the current president of the New York Head and Neck Society.

Selected Publications

Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. *Cancer Res*. 1993;53:4477-80.

Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1995;332:712-7.

Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 repression is a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. *J Natl Cancer Inst*. 1999;91:373-9.

Boyle JO, Lonardo F, Chang JH, Klimstra D, Rusch V, Dmitrovsky E. Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations. *Clin Cancer Res*. 2001;7:259-66.

Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. *Cancer Res*. 2005;65:664-70.

Gross ND, Boyle JO, Du B, et al. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. *ClinCancer Res*. 2007;13:5910-7.

Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. *Clinical Cancer Res*. 2008;14:2095-101.

Gümüş ZH, Du B, Kacker A, et al. Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. *Cancer Prev Res (Phila)*. 2008;1:100-11.

Duffield-Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. *Cancer Prev Res* (Phila). 2009;2:322-9.

Marc A. Cohen, MD, MPH

Assistant Attending Surgeon
Memorial Sloan Kettering Cancer Center

Education: MD, University of Pennsylvania
MPH, Columbia University

Residency: Hospital of the University of Pennsylvania

Fellowship: Princess Margaret Cancer Centre, Toronto General Hospital

Marc Cohen is a head and neck cancer and skull base surgeon who specializes in caring for people with cancerous and noncancerous tumors of the head and neck and skull base. The diseases he treats as part of the multidisciplinary skull base tumor team include skull base tumors such as sinus cancers, pituitary adenomas (tumors of the pituitary gland), meningiomas and craniopharyngiomas (brain tumors), and chordomas (tumors of the bones of the skull and spine). In addition, Dr. Cohen treats patients with head and neck and thyroid cancer. As part of the MSK team, he works to use minimally invasive surgical techniques whenever possible.

Dr. Cohen's research focuses on patients' outcomes after treatment for head and neck and skull base tumors. He is specifically interested in studying quality of life following minimally invasive and endoscopic surgeries, focusing on cancer treatments that offer the potential for the fewest possible side effects.

Selected Publications

Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA, Roman BR. Increasing Primary Surgical Treatment of T1 and T2 Oropharyngeal Squamous Cell Carcinoma and Rates of Adverse Pathologic Features; National Cancer Database. *Cancer* 2016

Patel SN, Cohen MA, Givi B, Dixon BJ, Gilbert RW, Gullane PJ, Brown DH, Irish JC, de Almeida JR, Higgins KM, Enepekides D, Huang SH, Waldron J, O'Sullivan B, Xu W, Su S, Goldstein DP. Salvage Surgery of Locally Recurrent Oropharyngeal Cancer. *Head Neck* 2016;38:658-64.

Quon H, Cohen MA, Montone K, O'Malley BW Jr, Weinstein GS. Transoral Robotic Surgery (TORS) and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16INK4a on Treatment Outcomes. *Laryngoscope* 2013; 123:635-40.

Cohen MA, Weinstein GS, O'Malley BW Jr, Feldman M, Quon H. Transoral Robotic Surgery (TORS) and Human Papillomavirus (HPV) Status: Oncologic Results. Head Neck 2011; 33:573-80.

Weinstein GS*, O'Malley BW Jr*, Cohen MA*, Quon H*. Transoral Robotic Surgery (TORS) for Advanced Oropharyngeal Carcinoma. *Arch Otolaryngol Head Neck Surg* 2010; 136:1079-85.

Weinstein GS, Quon H, O'Malley BW Jr , Kim GG, Cohen MA. Selective Neck Dissection and Deintensified Postoperative Radiation and Chemotherapy for Oropharyngeal Cancer: A Subset Analysis of the University of Pennsylvania Transoral Robotic Surgery Trial. *Laryngoscope* 2010; 120:1749-55.

Keefe SM, Cohen MA, Brose MS. Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications. *Clin Cancer Res* 2010:16(3):778-83.

Gabel BC*, Cohen MA*, Heuer GG, Pisapia J, Bohman LE, Leibowitz JM, O'Malley BW Jr., Grady MS. Comparison of Endoscopic and Microscopic Removal of Pituitary Adenomas: Single Surgeon Experience and the Learning Curve. *Neurosurg Focus* 2008; 25:E10.

Cohen MA, Liang J, Cohen IJ, Grady MS, O'Malley BW Jr., Newman JG. Endoscopic Resection of Advanced Stage Anterior Skull Base Lesions: Oncologically Safe? *ORL J Otorhinolaryngol Relat Spec* 2009; 71:123-8.

Cohen MA, Basha SB, Sewell DA. Increased Viral Load Correlates With Improved Survival in HPV-16 Associated Tonsil Carcinoma. *Acta Otolaryngol* 2008; 128:583

Ian Ganly, MD, PhD, MSc, FRCS(Gls,Ed), FRCS-ORL(Ed)

Associate Attending Surgeon
Memorial Sloan Kettering Cancer Center

Associate Professor of Otolaryngology
Weill Cornell Medical College

Education: MD, University of Glasgow
PhD, University of Glasgow
MSc, Columbia University

Residency: West of Scotland NHS Teaching Hospitals

Fellowship: Royal College of Physicians and Surgeons, Glasgow FRCS(Gls)
Royal College of Surgeons, Edinburgh FRCS(Ed)
Memorial Sloan Kettering Cancer Center

Ian Ganly was a clinical fellow at MSK from 2003 to 2005, during which time he was awarded the prestigious Michael E. Burt Fellow of the Year award for outstanding surgical excellence. Following his fellowship, he returned to his native Scotland, where he was an Attending Head and Neck Surgeon at the University of Edinburgh from 2005 to 2008. In 2008 he returned to MSK to take up his current position in the Head and Neck Service. Dr. Ganly has had fellowships in general surgery and otolaryngology–head and neck surgery from the Royal College of Surgeons, Edinburgh. He also has a PhD in molecular oncology from the University of Glasgow. Recently he was awarded an MSc in biostatistics and clinical research methods from the Mailman School of Public Health, Columbia University, New York.

His surgical interests are in thyroid surgery, skull base surgery, and minimally invasive surgery with trans-oral endoscopic laser and robotic surgery. His clinical research has largely focused on outcomes based on the development and analysis of large databases on thyroid cancer, salivary gland cancer, and oral cavity and oropharyngeal cancer. He also has strong interests in translational research focused on the application of genomics in thyroid and head and neck cancer. He collaborates with Dr. Timothy Chan and Dr. James Fagin at the Human Oncology Pathogenesis Program at MSK on these projects. He has been the principal investigator for MSK for the Cancer Genome Atlas thyroid cancer project and was responsible for the identification and recruitment of the thyroid cancer patients who participated in this study. He is currently carrying out genomics projects on Hurthle cell cancer and poorly differentiated thyroid cancer to identify the pathways involved in the pathogenesis of these cancers and identify potential targets for treatment

Selected Publications

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. *J Clin Invest*. 2016 Mar 1;126(3):1052-66.

Ganly I, Ibrahimpasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall cell features. *Thyroid*. 2014;24:662-70.

Ali S, Palmer FL, Yu C, Dilorenzo M, Shah JP, Kattan MW, Patel SG, Ganly I. Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. *Ann Surg Oncol*. 2014;21:637-42.

Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. *J Clin Endocrinol Metab*. 2013;98:E1562-6.

Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. *J Clin Endocrinol Metab*. 2013;98:E962-72.

Ibrahimpasic T, Ghossein R Md, Carlson DL, Chernichenko N, Nixon I, Palmer FL, Lee NY, Shaha AR Md, Patel SG, Tuttle RM Md, Balm AJ, Shah JP, Ganly I. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan Kettering Cancer Center experience. *Thyroid*. 2013;23:997-1002.

Ganly I, Goldstein D, Carlson DL, et al. Long-term regional control and survival in patients with "low-risk," early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. *Cancer*. 2013;119:1168-76.

Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer*. 2011;117:4439-46.

Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. *J Clin Oncol*. 2011;29:739-46.

Ganly I, Talbot S, Carlson D, et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. *J Clin Oncol*. 2007;25:1369-76.

Luc Morris, MD, MSc, FACS

Assistant Attending Surgeon
Catherine and Frederick J. Adler Chair for Junior Faculty
Memorial Sloan Kettering Cancer Center

Assistant Professor of Otolaryngology
Weill Cornell Medical College

Education: MD, New York University School of Medicine
MSc, Columbia University

Residency: NYU Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center

Luc Morris is an Assistant Attending Surgeon on the Head and Neck Service and holds an Adlerian Junior Faculty Chair at MSK. Luc grew up in Northern California, and attended Brown University, New York University School of Medicine, and Columbia University. After residency at NYU, he was a head and neck surgery fellow at MSK. He has clinical expertise in transoral laser microsurgery (TLM) for laryngeal and oropharyngeal tumors, and in the incorporation of these technologies into the broader landscape of evolving multidisciplinary therapies. He also heads an NIH-funded laboratory research group focused on cancer genomics as applied to squamous cell and salivary tumors, and an epidemiologic research program studying thyroid cancer overdiagnosis and overtreatment.

Selected Books

Luc GT Morris and Jatin P Shah. Technical Refinements in Head and Neck Surgery. Philadelphia: *JP Medical*, 2014.

Selected Publications

Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papilloma virus-associated oropharyngeal cancer. *J Clin Oncol.* 2011;29:739-46.

Morris LG, Taylor BS, Bivona T, et al. Genomic dissection of the EGFR/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. *Proc Natl Acad Sci U S A*. 2011;108:19024-9.

Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. *Nat Genet*. 2013;45:253-61.

Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the inf luence of access to care. *Thyroid*. 2014;23:885-91.

Morris LG, Riaz N, Desrichard A, Senbaboglu Y, Hakimi A, Makarov V, Reis-Filho JS, Chan TA. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. *Oncotarget* 2016;7:10051-63.

Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. *JAMA Otolaryngology* 2016 [Epub]

Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Dogan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL. The distinct molecular landscape of recurrent and metastatic head and neck cancers unveiled by a precision oncology sequencing platform. *JAMA Oncology* 2016 [Epub]

Dalin M, Desrichard AD, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. *Clinical Cancer Research* 2016 [Epub]

Snehal G. Patel, MD, MS, FRCS

Associate Attending Surgeon
Memorial Sloan Kettering Cancer Center

Associate Professor of Surgery
Weill Cornell Medical College

Education: MD, Shree Sayaji General Hospital & Medical College, Maharaja Sayajiro University of Baroda

Residency: Shree Sayaji General Hospital & Medical College

Fellowships: Tata Memorial Hospital, The Royal Marsden Hospital, Memorial Sloan Kettering Cancer Center

Snehal Patel is working to improve care of people with head and neck cancers with a multipronged research program that includes development of new technology for in vivo imaging and minimally invasive treatment of tumors; evaluation of patient expectations and development of novel patient education techniques; development of statistical methods for predicting individualized outcomes; and assessment of quality of care, patient satisfaction, and quality of life. He holds a US patient for a novel endoscopic laser-steering device that is currently being developed for minimally invasive surgical applications. His research efforts have been funded by intra- and extramural grants totaling over $1.5 million.

Selected Publications

Montero PH, Palmer FL, Shuman AG, et al. A novel tumor: specimen index for assessing adequacy of resection in early stage oral tongue cancer. *Oral Oncol*. 2014;50:213-20.

Montero PH, Yu C, Palmer FL, et al. Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. *Cancer*. 2014;120:214-21.

Bradbury M, Phillips E, Montero Miranda P, et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. *Integr Biol (Camb)*. 2013;5:74-86.

Nixon IJ, Ganly I, Hann LE, et al. Nomogram for predicting malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and cytologic features. *Surgery*. 2010;148:1120-7; discussion 1127-8.

Gil Z, Carlson DL, Boyle JO, et al. Lymph node density is a significant predictor of outcome in patients with oral cancer. *Cancer*. 2009;115:5700-10.

Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. *CA Cancer J Clin*. 2005;55:242-58.

Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. *Cancer*. 2003;98:1179-87.

Patel SG, Meyers P, Huvos AG, et al. Improved outcomes in osteogenic sarcoma of the head and neck. *Cancer*. 2002;95:1495-503.

Patel SG, Escrig M, Prasad M, et al. Primary malignant mucosal melanoma of head and neck. *Head Neck*. 2002;24:247-57.

Patel SG, See ACH, Williamson PA, Archer DJ, Rhys Evans PH. Radiation induced sarcoma of the head and neck. *Head Neck*. 1999;21:346-54.

Benjamin Roman, MD, MSHP

Assistant Attending Surgeon
Memorial Sloan Kettering Cancer Center

Assistant Professor of Surgery
Weill Cornell Medical College

Education: MD, Mount Sinai School of Medicine
MSHP, University of Pennsylvania School of Medicine

Residency: NYU Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center
University of Pennsylvania School of Medicine
Robert Wood Johnson Clinical Scholars Program

Benjamin Roman is a head and neck surgeon and health services researcher. Clinically, he specializes in the treatment of head and neck cancers, thyroid cancer, and skin cancer. Dr. Roman takes a team approach with his colleagues, focused on choosing individualized treatments to achieve the best outcomes.

Health services research in general aims to develop innovative ways to ensure the highest-quality and highest-value care so that patients can return to their lives as quickly as possible. Dr. Roman's research in healthcare delivery is based on this desire to individualize and improve treatment decisions. He takes pride in helping his patients navigate decisions regarding their cancer treatment and quality of life after treatment, based on the things that really matter to them.

Selected Publications

Wang, L. Y., Roman, B. R., Migliacci, J. C., Palmer, F. L., Tuttle, R. M., Shaha, A. R., & Ganly, I. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer*. 2015, 121(23):4132-40.

Marti, J. L., Davies, L., Haymart, M. R., Roman, B. R., Tuttle, R. M., & Morris, L. G. Inappropriate use of radioactive iodine for low-risk papillary thyroid cancer is most common in regions with poor access to healthcare. *Thyroid*. 2015, 25(7):865-6.

Roman, B. R., Goldenberg, D., & Givi, B. Guideline recommended follow-up and surveillance of head and neck cancer survivors. *Head and Neck*. 2015, 38(2):168-74.

Roman, B. R. On marginal health care–probability inflation and the tragedy of the commons. *N Engl J Med*. 2015, 372(6):572-5.

Roman, B. R., Patel, S. G., Wang, M. B., Pou, A. M., Holsinger, F. C., Myssiorek, D., & Shea, J. A. Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. *J Natl Compr Canc Netw.* 2015, 13(1):69-77.

Roman, B. R., Feingold, J. H., Patel, S. G., Shaha, A. R., Shah, J. P., Tuttle, R. M., & Epstein, A. J. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1cm. *Thyroid*. 2014, 24(10):1549-50.

Roman, B. R., Awad, M. I., & Patel, S. G. Defining value-driven care in head and neck oncology. *Curr Oncol Rep.* 2015, 17(1):424.

Roman, B. R., & Feingold, J. Patient-centered guideline development: best practices can improve the quality and impact of guidelines. *Otolaryngol Head Neck Surg*. 2014, 151(4):530-2.

Roman, B. R., & Asch, D. A. (2014). Faded promises: the challenge of deadopting low-value care. *Ann Intern Med*. 2014, 161(2):149-50

Jatin Shah, MD

Senior Attending Surgeon
Elliot W. Strong Chair in Head and Neck Oncology
Memorial Sloan Kettering Cancer Center

Professor of Surgery
Weill Cornell Medical College

Education: MD, Medical College, MS University, Baroda (India)

Residency: New York Infirmary

Fellowship: Memorial Sloan Kettering Cancer Center

Jatin Shah has extensive experience and expertise in all aspects of head and neck surgery, including skull base and sinus surgery, salivary and thyroid tumors, and tumors of the oral cavity, pharynx, larynx, and trachea. He has developed many new surgical procedures for access and resection at the skull base and for laryngo-tracheal and mediastinal tumors. He has devised and revised many surgical procedures to preserve organ function and facial appearance to a far greater degree than was previously possible. His technical expertise is known worldwide.

Dr. Shah has been actively involved in training the next generation of hundreds of head and neck cancer surgeons for the past four decades. Under his leadership, the MSK fellowship program has been supported by an NIH T32 grant since 1992. The fellowship program draws talented surgeons to MSK from all over the world who train either as fellows or observers. In addition, Dr. Shah has developed the unique Global Online Fellowship program, from which nearly 200 surgeons from 49 countries are currently receiving training.

In addition to his clinical, teaching, training, and research activities at MSK, Dr. Shah is actively involved in head and neck oncology both nationally and internationally. He has served as president of the Society of Head and Neck Surgeons, the North American Skull Base Society, the New York Head and Neck Society, the New York Cancer Society, and the International Academy of Oral Oncology. He founded the International Federation of Head and Neck Oncologic Societies and serves as its Chief Executive Officer. The award-winning textbooks written by him are state-of-the-art resources in head and neck surgery. Over the years, he has also served in varying capacities on the American Board of Surgery, the Commission on Cancer of the American College of Surgeons, as Chairman of the Advanced Training Council for Head and Neck Surgery as well as Chairman of the Head and Neck task force of the American Joint Committee on Cancer. In recognition of his extraordinary contributions to the field, MSK has established the Jatin Shah Chair in Head and Neck Surgery and Oncology.

Selected Books

Jatin Shah's Head and Neck Surgery and Oncology. 4th ed. Shah JP, Patel SG, Singh B, eds. Philadelphia: Elsevier; 2012.

Oral Cancer. Shah JP, Johnson NW, Batsakis JG, eds. London: Martin Dunitz; 2003

Cancer of the Head and Neck. Shah JP, ed. Toronto: BC Decker; 2001.

Essentials of Head and Neck Oncology. Close LG, Larson DL, Shah JP, eds. New York: Thieme; 1998

Selected Publications

Shah JP. Patterns of nodal metastases from squamous carcinomas of the upper aerodigestive tract. *Am J Surg* 1990, 160:405-409.

Shah JP and Ihde J. Salivary Gland Tumors. *Curr Prob Surg*, 1990, 27:772-883.

Shah JP. The making of a head and neck surgeon. *Am J Surg*, 1991, 162:284-287.

Shah JP, Loree T, Dharkar D, and Strong EW. Prognostic factors in differentiated carcinoma of the thyroid. *Am J Surg*. 1992, 164:658-661.

Shah JP and Andersen PE. The impact of patterns of neck metastasis on modifications of neck dissection. *Ann Surg Onc* 1994;1:521-532.

Shah JP. The Making of a Specialty. *Am J Surg,* 1998, 176:398-403.

Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, deSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata S, Kowalski LP, Kraus DH, Levine PA, dos Santos LRM, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP. Craniofacial surgery for malignant skull base tumors: Report of an international collaborative study. *Cancer* 2003 Sept 15; 98(6):1179-87.

Shah JP. Head and Neck Surgery in crisis :Preparing for the future. Commentary. Arch. *Otol Head Neck Surg*. 2005, July, 131:556-560

Ashok Shaha, MD, FACS

Attending Surgeon
Jatin P. Shah Chair in Head and Neck Surgery
Memorial Sloan Kettering Cancer Center

Professor of Surgery
Weill Cornell Medical College

Education: Medical College, University of Baroda (India)

Residency: SUNY Downstate Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center

After completing his fellowship in Head and Neck Surgery at Memorial Sloan Kettering Cancer Center, Ashok Shaha was the Chief of Head and Neck Surgery at Downstate Medical Center for 11 years. Since his return to MSK, Dr. Shaha has been actively involved in various aspects of head and neck surgery, with a recent specialization in thyroid and parathyroid surgery.

Dr. Shaha is actively involved in clinical research in head and neck cancer with special interest in thyroid cancer. We have a large number of publications in the field of management of thyroid cancer, especially related to risk group stratification. Dr. Shaha's other clinical research includes cancer of the oral cavity, oropharynx, and laryngopharyngeal areas.

Selected Publications

Shaha AR. Recurrent differentiated thyroid cancer. *Endocr Pract*. 2012;18(4): 600-603.

Shaha AR. Training of a thyroid surgeon: from scalpel to robot. *Surgery* 2012;152 (6): 943-952.

Shaha AR. Central compartment dissection for papillary thyroid cancer. *Br J Surg*. 2013;(4): 438-439.

Shaha AR. Right paraesophageal lymph node metastasis. *Eur J Surg Oncol.* 2016 Jan;42(1):79-80. Epub 2015 Nov 11.

Shaha AR. Anaplastic thyroid cancer: large database, cautious interpretations. *Ann Surg Oncol*. 2015 Jul 29.

Shaha AR. Substernal goiter: what is in a definition? Surgery. 2010; 147(2):239-40.

Shaha AR. Revision thyroid surgery - technical considerations. *Otolaryngol Clin North Am*. 2008 Dec; 41 (6); 1169-83.

Shaha AR, Training in head and neck surgery and oncology. *J Surg Oncol*. 2008 Jun 15; 97(8): 717-20.

Shaha AR. TNM classification of thyroid carcinoma. *World J Surg*. 2007 May; 31(5):879-87.

Shaha AR. Advances in the management of thyroid cancer. *Int J Surg* 2005; 3:213-220.

Bhuvanesh Singh, MD, PhD, FACS

Attending Surgeon
Director, Laboratory of Epithelial Cancer Biology
Director, Speech and Hearing Center
Memorial Sloan Kettering Cancer Center

Professor of Otolaryngology
Weill Cornell Medical College

Education: MD, SUNY Downstate College of Medicine
PhD, Netherlands Cancer Institute, University of Amsterdam

Residency: SUNY Downstate Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center

In addition to providing clinical care to patients with head and neck cancer, Bhuvanesh Singh helped to establish the Advanced Skin Cancer Management and Prevention Program at MSK. His laboratory focuses on the identification of novel approaches to treating head and neck cancer.

Dr. Singh's work was among the first to identify the significance of the PIK3CA/AKT pathway in head and neck and lung cancers. His laboratory also identified a novel gene, SCCRO, and revealed the gene as a major driver of the behavior of head and neck cancer, as well as many other human cancers. His team's findings have been validated by results and analysis performed by The Cancer Genome Atlas, not only in head and neck cancers, but also in lung, ovarian, cervical, and breast cancers. Having defined the biochemical function of SCCRO, Dr. Singh and his collaborators went on to complete a high-throughput screen and identified novel lead compounds, which they are now developing for use in human trials.

Selected Publications

Kutler DI, Wreesmann V, Goberdhan A, et al. Higher levels of human papilloma virus integration and lack of p53 mutations in squamous cell carcinoma from patients with Fanconi anemia. *J National Cancer Inst*. 2003;95:1718-21.

Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. *Genes Dev*. 2002;16:984-93.

Singh B, Gogineni SK, Sacks PG, et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification.*Cancer Res*. 2001;61:4506-13.

Sarkaria I, O-Charoenrat P, Talbot SG, et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. *Cancer Research Oct*. 2006;66:9437-44.

Kim AY, Bommelje CC, Lee BE, et al. SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. *J Biol Chem*. 2008;283:33211-20.

Bommelje CC, Weeda VB, Huang G, et al. Oncogenic function of SCCRO5/DCUN1D5 requires its neddylation E3 activity and nuclear localization. *Clin Cancer Res*. 2014;20:372-81.

Broderick SR, Golas BJ, Pham D, et al. SCCRO promotes glioma formation and malignant progression in mice. *Neoplasia*. 2010;12:476-84.

Huang G, Kaufman AJ, Ramanathan Y, Singh B. SCCRO (DCUN1D1) Promotes nuclear translocation and assembly of the neddylation E3 complex. *J BiolChem*. 2011;286:10297-304.

Ganly I, Talbot S, Carlson D, et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. *J Clin Oncol*. 2007;25:1369-76.

Wreesmann WB, Shi W, Thaler HT, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. *J Clin Oncol*. 2004;22:3965-72

Brian R. Untch, MD

Assistant Attending Surgeon
Head and Neck Service
Gastric and Mixed Tumor Service
Memorial Sloan Kettering Cancer Center

Assistant Professor of Surgery
Weill Cornell Medical College

Education: MD, Stritch School of Medicine

Residency: Duke University Medical Center

Fellowship: Memorial Sloan Kettering Cancer Center

Brian Untch is a board-certified surgeon who cares for patients with benign and cancerous endocrine and neuroendocrine (carcinoid) tumors. This includes diseases of the parathyroid, thyroid, adrenal glands and the gastrointestinal tract. Because these conditions are often complex, Dr. Untch works closely with colleagues in endocrinology, medical oncology, radiology, gastroenterology and pathology to deliver state-of-the art multidisciplinary care. In addition to endocrine and neuroendocrine conditions, Dr. Untch also has a special interest in caring for patients with genetic and familial endocrine diseases including Multiple Endocrine Neoplasia (MEN) I, IIa, and IIb, von Hippel-Lindau Syndrome (VHL), paraganglioma syndromes, Cowden's Disease, familial hyperparathyroidism, familial medullary thyroid cancer, and Carney Complex.

Dr. Untch's research focuses on mechanisms of thyroid and neuroendocrine tumor progression and responses to therapy in the Human Oncology and Pathogenesis Program. Using genetically accurate models of cancer, he explores why certain tumors are more aggressive than others (such as poorly differentiated or anaplastic thyroid cancers) and how best to treat these with various interventions. Dr. Untch has been awarded multiple grants including those from the American Thyroid Association, the American Surgical Association, the Dana Foundation and the American Association of Endocrine Surgeons.

Selected Publications

Tang LH, Untch BR, Dhall D, Jih L, Reidy DL, O'Reilly EO, Vakiani E, Basturk O, Shia J, Sigel C, Allen PJ, Klimstra DS. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly fifferentiated neuroendocrine carcinomas. *Clin Cancer Res* 2016; 15:1011-7

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Knauf JA, Smith V, Ganly I, Taylor B, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R and Fagin JA.NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. *Cancer Disc* 2015; 5:1178-93

Untch BR, Palmer F, Ganly I, Patel S, Tuttle R, Shah J, Shaha A. Oncologic outcomes after selective completion thyroidectomy for patients with well-differentiated thyroid carcinoma. *Ann Surg Oncol* 2014; 21:1374-8.

Untch BR, Gyorki DE, Tuttle MD, Shaha AR. Prophylactic central neck dissection in differentiated thyroid cancer – an assessment of the evidence. *Ann Surg Onc* 2013; 20:2285-9.

Untch BR, Adam MA, Scheri RP, Leight GS, Olson JA. Tumor proximity to the recurrent laryngeal nerve in patients undergoing surgery for primary hyperparathyroidism. *Ann Surg Oncol* 2012; 19: 3823-6.

Untch BR, Abdelgadir Adam M, Scheri RP, Leight GS, Olson JA. Surgeon-performed ultrasound is more accurate than 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: Results in 516 patients over 10 years. *J Am Coll Surg* 2011;212:522-9.

Koh JJ, Dar M, Untch BR, Spurney RR, Dixit D, Marks JR, Dressman HK, Saito W, Olson JA Jr. Regulator of G-protein signaling 5 (RGS5) modulates human calcium sensing receptor and is variably expressed in primary hyperparathyroidism. *Mol Endo* 2011;25:867-76.

Abdelgadir Adam M, Untch BR, Danko ME, Stinnett S, Dixit D, Koh JJ, Marks JR, Olson JA Jr. Severe obesity is associated with greater symptoms, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. *J Clin Endocrinol Metab* 2010; 95:4917-24.

Abdelgadir Adam, M, Untch BR, Olson JA Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. *Oncologist* 2010: 15;61-72.

RECENT PUBLICATIONS BY MSK HEAD AND NECK SURGERY FELLOWS

2011

Nixon IJ, Palmer FL, Whitcher MM, Shaha AR, Shah JP, Patel SG and Ganly I. Thyroid isthmusectomy for well differentiated thyroid cancer. *Ann Surg Oncol* 2011; 18:767-770.

Iyer NG, Nixon IJ, Palmer F, Ganly I, Patel SG, Shaha AR. Electronic synoptic operative reporting for thyroid surgery using an electronic data management system: potential for prospective multicenter data collection. *Ann Surg Oncol.* 2011; 18(3):762-6.

Iyer NG, Shaha AR. Central compartment dissection for well differentiated thyroid cancer and the band plays on. *Curr Opin Otolaryngol Head Neck Surg*. 2011; 19(2):106-12.

Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer*. 2011, 117 (19), p. 4439.4446.

O'Neill JP, Shaha AR. Nutrition Management of Patients with Malignancies of the Head and Neck. *Surg Clin North Am*. 2011; 91(3):631-9.

Mohebati A, Shaha AR. Anatomy of thyroid and parathyroid glands and neurovascular relations. *Clin Anat*. 2011;. Doi: 10. 1002/ca.21220.

Nixon IJ, Ganly I, Palmer FL, Whitcher M, Patel SG, Tuttle RM, Shaha A and Shah JP. Disease –related death in patients who were considered free of macroscopic disease after initial treatment of well differentiated thyroid carcinoma. *Thyroid*. 2011; 1-4.

Morris LG, Mehra S, Shah JP, Bilsky MH, Selesnick SH, Kraus DH. Predictors of survival and recurrence after temporal bone resection for cancer. *Head Neck*. 2011; 23. doi: 10.1002/hed.21883.

Gil Z, Fliss DM, Cavel O, Shah JP, Kraus DH. Improvement in survival during the past 4 decades among patients with anterior skull base cancer. *Head Neck*. 2011;doi: 10.1002/hed.21886

Iyer NG, Nixon IJ, Palmer F, Kim L, Whitcher M, Katabi N, Ghossein R, Shah JP, Patel SG, Ganly I. Surgical management of squamous cell carcinoma of the soft palate: Factors predictive of outcome. *Head Neck*. 2011;10.1002/hed.21878

2012

Chernichenko N, Shaha AR. Role of tracheal resection in thyroid cancer. *Curr Opin Oncol*. 2012; 24 (1): 29-34. Review.

Mohebati A, Shaha AR. Imaging techniques in parathyroid surgery for primary hyperparathyroidism. 2012 *Am J Otolaryngology – Head and Neck Medicine and Surgery* 33 2012;(4), pp. 457-468.

Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP.Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy.*Surgery*. 2012;151(4):571-9

Shuman AG, Shaha AR, Tuttle RM, Fins JJ, Morris LG. Medullary Thyroid Carcinoma: Ethical Issues for the Surgeon. *Ann Surg Oncol*.2012; 19(7):2102-7. doi: 10.1245/s10434-012-2235-4.

Givi B, Linkov G, Ganly I, Patel SG, Wong RJ, Singh B, Boyle JO, Shaha AR, Shah JP, Kraus DH. Selective neck dissection in node-positive squamous cell carcinoma of the head and neck. *Otolaryngol Head Neck Surg*. 2012;147(4):707-15.

Nixon IJ, Whitcher M, Palmer FL, Shaha AR Md, Shah JP, Patel S, Ganly I. The Impact of Distant Metastases at Presentation on Prognosis in Patients Differentiated Carcinoma of the Thyroid Gland. *Thyroid*. 2012;884-9.

Nixon IJ, Ganly I, Hann LE, Yu C, Palmer FL, Whitcher MM, Shah JP, Shaha A, Kattan MW, Patel SG. Nomogram for selecting thyroid nodules for ultrasound-guided fine-needle aspiration biopsy based on a quantification of risk of malignancy. *Head Neck*. 2012;1022-5.

Iyer NG, Kim L, Nixon IJ, Palmer F, Shah JP, Patel SG, Ganly I. Outcome of patients with early T1 and T2 squamous cell carcinoma of the base of tongue managed by conventional surgery with adjuvant postoperative radiation. *Head Neck*. 2012; 999-1006. doi: 10.1002/hed.23071.

Mohebati A, Ganly I, Busam KJ, Coit D, Kraus DH, Shah JP, Patel SG. The Role of Sentinel Lymph Node Biopsy in the Management of Head and Neck Desmoplastic Melanoma.*Ann Surg Oncol*. 2012; (13):4307-13. doi: 10.1245/s10434-012-2468-2.

Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I.The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. *Thyroid*. 2012;22(9):884-9.

2013

Givi B, Liu J, Bilsky M, Mehrara B, Disa J, Pusic A, Cordeiro P, Shah JP, Kraus DH. Outcome of resection of infratemporal fossa tumors. *Head Neck*. 2013; (11):1567-72. doi: 10.1002/hed.23186.

Shuman AG, Patel S, Shah JP, Korc-Grodzicki B. Optimizing perioperative management of geriatric head and neck cancer patients. *Journal of Surg Oncol*. 2013; (5):743-9. doi: 10.1002/hed.23347.

Shuman AG, McKiernan JT, Thomas D, Patel P, Palmer F, Shaffer BT, Shah JP, Patel SG, Boyle JO. Outcomes of a head and neck cancer screening clinic. *Oral Oncol* 2013; 49(12):1136-40. doi: 10.1016/j.oraloncology.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA. The mutational landscape of adenoid cystic carcinoma. *Nat Genet*. 2013;45(7):791-8.

Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A,Shah JP. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan Kettering Cancer Center risk group stratification. *Thyroid*. 2013;23(6):683-94.

Amit M, Yen TC, Liao CT, Binenbaum Y, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Cernea CR, Brandao SJ, Kreppel M, Zöller J, Fliss D, Bachar G, Shpitzer T, Bolzoni VA, Patel PR, Jonnalagadda S, Robbins KT, Shah JP, Patel SG, Gil Z. Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research. International Consortium for Outcome Research (ICOR) in Head and Neck Cancer. *Ann Surg Oncol*. 2013;20(11):3575-81.

Shuman AG, Korc-Grodzicki B, Shklar V, Palmer F, Shah JP, Patel SG. A new care paradigm in geriatric head and neck surgical oncology. J Surg Oncol. 2013;108(3):187-91.

Patel SG, Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Cernea CR, Brandao SJ, Kreppel M, Zöller J, Fliss D, Fridman E, Bachar G, Shpitzer T, Bolzoni VA, Patel PR, Jonnalagadda S, Robbins KT, Shah JP, Gil Z. Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research. *Br J Cancer*. 2013;109(8):2087-95.

Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Kreppel M, Zöller J, Fridman E, Bolzoni VA, Shah JP, Binenbaum Y, Patel SG, Gil Z. Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. *Cancer*. 2013; 119:4242-4248.

Shuman AG, McKiernan JT, Thomas D, Patel P, Palmer FL, Shaffer BT, Shah JP, Patel SG, Boyle JO. Outcomes of a head and neck cancer screening clinic. *Oral Oncology*. 2013; 49:1136-1140.

2014

Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LGT. Decision making in the management of recurrent head and neck cancer. *Head and Neck. 2014*; 36:144-151.

Montero PH, Yu C, Palmer FL, Patel PD, Ganly I, Shah JP, Shaha AR, Boyle JO, Kraus DH, Singh B, Wong RJ, Morris LG, Kattan MW, Patel SG. Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. *Cancer*. 2014; 120:214-221.

Montero PH, Palmer FL, Shuman AG, Patel PD, Boyle JO, Kraus DH, Morris LG, Shah JP, Shaha AR, Singh B, Wong RJ, Ganly I, Patel SG. A novel tumor: Specimen index for assessing adequacy of resection in early stage oral tongue cancer. *Oral Oncology*. 2014; 50:213-220.

Nixon IJ, Shah JP. Well differentiated thyroid cancer: Are we over treating our patients?. *European Journal of Surgical Oncology*. 2014; 40:129-132.

Mohebati A, DiLorenzo M, Palmer F, Patel SG, Pfister D, Lee N, Tuttle RM, Shaha AR, Shah JP, Ganly I. Anaplastic thyroid carcinoma: A 25-year single-institution experience. *Annals of Surgical Oncology* .2014; 21:1665-1670.

Shuman AG, Patel SG, Shah JP, Korc-Grodzicki B. Optimizing perioperative management of geriatric patients with head and neck cancer. *Head and Neck*. 2014; 36:743-749.

Rahmati R, Dogan S, Pyke O, Palmer F, Awad M, Lee N, Kraus DH, Shah JP, Patel SG, Ganly I. Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation. *Head Neck*. 2015;37(6):800-7. doi: 10.1002/hed.23679.

Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP, Kreppel M, Cernea CR, Bachar G, Villaret AB, Fliss D, Fridman E, Robbins KT, Shah JP, Patel SG, Gil Z. Minimum Nodal Yield in Oral Squamous Cell Carcinoma: Defining the Standard of Care in a Multicenter International Pooled Validation Study. *Ann Surg Oncol*. 2014;21:3049-3055.

Nixon IJ, Wang LY, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. The impact of nodal status on outcome in older patients with papillary thyroid cancer. *Surgery*. 2014;156(1):137-46.

Wang LY, Palmer FL, Thomas D, Shaha AR, Shah JP, Patel SG, Tuttle RM, Ganly I. Preoperative neck ultrasound in clinical node negative differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2014;99:3686-3693.

2015

Roman BR, Patel SG, Wang MB, Pou AM, Holsinger FG, Myssiorek D, Goldenberg D, Swisher-McClure S, Lin A, Shah JP, Shea JA. Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. *Jour Nat Compre Can Net*. 2015;13:69-77.

Wang LY, Palmer FL, Nixon IJ, Tuttle RM, Shah JP, Patel SG, Shaha AR, Ganly I. Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. *Ann Surg Oncol*. 2015; (11):3530-6. doi: 10.1245/s10434-015-4398-2.

Wreesmann V, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle MM, Shah JP, Patel SG, Ghossein RA. Prognostic Value of Vascular Invasion in Well Differentiated Papillary Thyroid Carcinoma. *Thyroid*. 2015;25(5):503-8. doi: 10.1089/thy.2015.0052.

Dooley L, Shah J. Management of the neck in maxillary sinus carcinomas. *Curr Opin Otolaryngol Head Neck Surg*. 2015;23(2):107-14.

Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, Patel SG, Shah JP, Ganly I. Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. *Ann Surg Oncol*. 2015. [Epub ahead of print]

Wang LY, Palmer FL, Migliacci JC, Nixon IJ, Shaha AR, Shah JP, Tuttle RM, Patel SG, Ganly I. Role of RAI in the management of incidental N1a disease in papillary thyroid cancer. Clin Endocrinol (Oxf). 2015. [Epub ahead of print]

Wang LY, Ghossein R, Palmer FL, Nixon IJ, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. *Thyroid*. 2015;25(9):993-8. doi: 10.1089/thy.2015.0141.

Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. *Ann Surg Oncol*. 2015. [Epub ahead of print].

Wang LY, Roman BR, Migliacci JC, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer. 2015*. [Epub ahead of print].

Mizrachi A, Swartzwelder CE, Shaha AR. Proposal for anatomical classification of the superior pole in thyroid surgery. *J Surg Oncol*. 2015;112(1):15-7. doi: 10.1002/jso.23950.

HEAD AND NECK SERVICE ALUMNI (1979-2015)

1979-1980	Richard A. Lopchinsky General Surgery, Phoenix, AZ
1980-1981	Gaetano DeRose General Surgery, London Health Sciences, London, ON, Canada
1981-1982	Ashok R. Shaha Attending Surgeon, Head and Neck Service, MSK, New York, NY
1982-1983	Walter King Director, Plastic and Reconstructive Surgery, Santitorium Hospital, Hong Kong
1983-1984	Larry Sheman ENT, Private Practice, New York, NY
1984-1985	Barry Wenig Director of the Head and Neck Surgery Center, University of Illinois, Chicago, Il
1985-1986	Robert T. Parrish ENT, Midwest ENT Associates, Peoria, Il
1986-1988	Soo Khee Chee Director of the National Cancer Center of Singapore
1987-1988	Jeffrey Spiro ENT, University of Connecticut, Farmington CT
1988-1989	Thomas R. Loree Otolaryngology/Surgery, Sisters of Charity Hospital, Buffalo, NY
1989-1990	Sanford Dubner Head and Neck Surgery, North Shore LIJ, New Hyde Park, NY
1990-1991	Dennis Kraus Director of the New York Head and Neck Institute, North Shore LIJ, New York, NY

1991-1992 Mark DeLacure
Associate Professor, Otolaryngology,
NYU Langone Medical Center, New York, NY

1992-1994 Bruce Davidson
Professor and Chair, Otolaryngology,
Georgetown University, Washington DC

1993-1994 Christopher Hughes
Consultant Head and Neck Surgeon,
St. Vincent's Hospital, Sydney, Australia

1993-1995 Peter Andersen
Otolaryngology, OHSU, Portland, OR

1993-1995 William Lydiatt
Director, Head and Neck Surgery, Vice Chair,
Otolaryngology, University of Nebraska,
Omaha, NE

1994-1996 Daniel Kelley
ENT Private Practice, Salisbury, MD

1995-1996 Gary Morgan
Clinical Associate Professor, University of
Sydney, Australia

1996-1997 Paul Friedlander
Associate Professor and Chair of Otolaryngology,
Tulane University, New Orleans, LA

1995-1997 Sal Caruana
Otolaryngology, New York Presbyterian,
Columbia and Cornell, New York, NY

1996-1998 Dennis Teck-Hock Lim
Head and Neck Surgeon, Private Practice,
Mt. Elizabeth Hospital, Singapore

1997-1998 Anthony Tufaro
Vice Chair of Plastic Surgery, Johns Hopkins
Medical Center, Baltimore, MD

1996-1998 Jay O. Boyle
Associate Attending Surgeon, Head and Neck
Service, MSK, New York, NY

1997-1999 John Carew
Otolaryngology Head and Neck Surgery,
Private Practice, New York, NY

1997-1999 Bhuvanesh Singh
Attending Surgeon, Head and Neck Service,
MSK, New York, NY

1998-2000 Paul Kodeshian
Head and Neck Surgeon, Ronald Reagan
UCLA Medical Center, Santa Monica, CA

1998-2000 Snehal G. Patel
Associate Attending Surgeon, Head and Neck
Service, MSK, New York, NY

199-2000 Joseph Califano
Professor of Otolaryngology, Johns Hopkins
Medical Center, Baltimore, MD

1999-2001 Richard J. Wong
Chief, Head and Neck Service, MSK,
New York, NY

2000-2003 Brandon G. Bentz
Otolaryngology, Salt Lake City, UT

2001-2002 Maria Evasovich
Surgical Oncologist, University of Minnesota
Medical Center, Minneapolis, MN

2002-2003 Erik Cohen
Director of Head and Neck Surgery, Morristown
Medical Center, Morristown, NJ

2001-2004 David Kutler
Associate Attending, New York Presbyterian,
Cornell University, New York, NY

2002-2004 Ellie Maghami
Chief, Head and Neck Surgery, City of Hope,
Duarte, CA

2003-2004 Kepal Patel
Chief, Division of Endocrine Surgery,
NYU Langone Medical Center, New York, NY

2003-2005 Ian Ganly
Associate Attending Surgeon, Head and Neck
Service, MSK, New York, NY

2002-2005 Neil Gross
Head and Neck Surgeon, MD Anderson Cancer
Center, Houston, TX

2003-2005 Susan McCammon
Associate Professor of Otolaryngology,
University of Texas Medical Branch, League City, TX

2005-2007 Jennifer Bocker
Head and Neck Surgery Private Practice, Golden, CO

2007-2009 Jerry Castro
ENT, Guam Memorial Hospital, Tamuning, Guam

2008-2009 Silvio Ghirardo
Attending Surgeon, Mercy Medical Center,
Cedar Rapids, IA

2007-2009 Vincent Reid
Attending Surgeon, Mercy Medical Center,
Cedar Rapids, IA

2006-2008 Vishal Choksi
Chief of Head and Neck Surgery, Apollo Hospitals,
Ahmedbad, India

2006-2008 Ziv Gil
Chairman, Otolaryngology, Rambam Medical
Center, Haifa, Israel

2007-2008 Patrick Sheahan
Consultant Otolaryngologist, South Infirmary Victoria University Hospital, Cork, Ireland

2007-2009 Benjamin Judson
Assistant Professor of Otolaryngology, Yale School of Medicine, New Haven, CT

2007-2010 Daniel Price
Assistant Professor of Otolaryngology, Mayo Clinic, Rochester, MN

2007-2009 Ben Saltman
Assistant Professor of Otolaryngology, North Shore LIJ, New Hyde Park, NY

2008-2009 Nishant Agrawal
Associate Professor of Otolaryngology, Johns Hopkins Medical Center, Baltimore, MD

2008-2009 Hin Ngan Tay Otolaryngologist, Head and Neck Surgeon, Mt. Elizabeth Hospital, Singapore

2008-2010 Babak Givi
Assistant Professor of Otolaryngology, NYU Langone Medical Center, New York, NY

2008-2010 Jeffrey Liu
Assistant Professor of Otolaryngology, Temple University, Philadelphia, PA

2009-2010 Arnbjorn Toset
General Surgery, Private Practice, Long Island, NY

2011-2012 Iain Nixon
Consultant ENT Surgeon, William Harvey Hospital, Kent, UK

2009-2010 Gopal Iyer
Consultant Head and Neck Surgeon, Singapore General Hospital, Singapore

2010-2011 Arash Mohebati
General Surgery, John Muir Health, Walnut Creek, CA

2009-2011 Luc Morris
Assistant Attending Surgeon, Head and Neck Service, MSK, New York, NY

2010-2011 Rahmatullah Rahmati
Assistant Professor, New York Presbyterian, Columbia University, New York, NY

2010-2011 James Paul O'Neill
ENT, St. James and The Royal Victoria Eye and Ear Hospital, Dublin, Ireland

2011-2013 Volkert Wreesmann
Head and Neck Surgeon, Netherlands Cancer Institute, Amsterdam, The Netherlands

2010-2012 Natalya Chernichenko
Chief of Head and Neck Surgery, SUNY Downstate Medical Center, Brooklyn, NY

2011-2014 Allen Ho
Attending Head and Neck Surgeon, Cedars-Sinai Medical Center, Los Angeles, CA

2011-2013 Andrew G. Shuman
Assistant Professor of Otolaryngology, University of Michigan, Ann Arbor, MI

2012-2014 Mina Le
Otolaryngology, West Palm Beach VA Medical Center, Riviera Beach, FL

2012-2014 William McNamara
General Surgery, Medical City Hospital, Dallas, TX

2012-2015 Benjamin R. Roman
Assistant Attending Surgeon, Head and Neck Service, MSK, New York, NY

2013-2014 Yamil Castillo-Beauchamp
General Surgery, San Juan, Puerto Rico

2013-2015 Pablo Montero Miranda
General Surgery, University Hospital, Santiago, Chile

2012-2015 Andres Lopez-Albaitero
ENT, Private Practice, New York, NY

2013-2015 Laura M. Dooley
Assistant Professor of Otolaryngology, University of Missouri School of Medicine, Columbia, MO

Memorial Sloan Kettering
Cancer Center

Head and Neck Oncologic Surgery Fellowship Program

1275 York Avenue
New York, NY 10065
www.mskcc.org

Rasha Jadalhack, MPA
Education Program Manager
Department of Surgery

T 212-639-3936
F 212-717-3169
jadalhar@mskcc.org